We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Maximus Benefits From Buyouts & Strong Cash Flow From Operations
Read MoreHide Full Article
Maximus, Inc. (MMS - Free Report) is benefiting from a robust relationship with governments, enabling it to secure long-term contracts. Buyouts expand its business processes and strengthen its client base. Dividend-seeking investors will find this stock appealing. Robust liquidity reassures the company’s financial position.
MMS reported better-than-expected first-quarter fiscal 2025 results. Quarterly adjusted earnings of $1.61 per share beat the Zacks Consensus Estimate by 15.8% and increased 20.2% on a year-over-year basis. Revenues of $1.4 billion topped the consensus mark by 7% and rose 5.7% from the year-ago quarter.
How is Maximus Faring?
The company maintains strong relationships with governments, and the long-term contracts provided by the government create a predictable recurring revenue stream. MMS seeks long-term relationships with clients in both existing and adjacent markets.
Maximus also concentrates on expanding its foothold in clinical services, as well as long-term services and support. Longevity and complex health issues have increased the need for government social benefits and safety-net programs. We believe that this should continue driving demand for the company’s services.
Acquisitions enable MMS to expand its business processes, knowledge and client relationships, enhance technical capabilities, and gain additional skill sets. Strategic acquisitions also complement the company’s long-term organic growth strategy. In 2024, the company acquired part of a vendor who had performed IT services for Maximus over several years for $18 million in cash. The 2022 acquisition of Stirling Institute of Australia has strengthened its employment services. BZ Bodies' buyout has strengthened MMS’s services in the U.K.
Maximus banks on the subject matter expertise of its workforce in the critical aspects of the design, implementation, and operation of government health and human services programs. Its ability to deliver defined, measurable outcomes differentiates MMS.
The company generates a strong cash flow from operations due to its profitable business and efficient receivables management. In case of an urgent requirement for working capital, MMS can borrow $600 million via a credit agreement with JPMorgan Chase N.A. All these factors provide the company with a competitive edge over its peers.
In fiscal 2021, 2022, 2023 and 2024, Maximus paid out cash dividends of $68.8 million, $68.7 million, $68 million and $72.9 million, respectively. These steady payouts indicate the company’s commitment to creating value for shareholders and underline its confidence in its business.
MMS’s current ratio (a measure of liquidity) at the end of first-quarter fiscal 2025 was pegged at 1.72, higher than the industry’s 1.54. A current ratio of more than 1 indicates that the company should not have problems meeting its short-term obligations.
Image Source: Zacks Investment Research
Zacks Rank & Other Stocks to Consider
MMS currently flaunts a Zacks Rank #1 (Strong Buy) at present.
Image: Bigstock
Maximus Benefits From Buyouts & Strong Cash Flow From Operations
Maximus, Inc. (MMS - Free Report) is benefiting from a robust relationship with governments, enabling it to secure long-term contracts. Buyouts expand its business processes and strengthen its client base. Dividend-seeking investors will find this stock appealing. Robust liquidity reassures the company’s financial position.
MMS reported better-than-expected first-quarter fiscal 2025 results. Quarterly adjusted earnings of $1.61 per share beat the Zacks Consensus Estimate by 15.8% and increased 20.2% on a year-over-year basis. Revenues of $1.4 billion topped the consensus mark by 7% and rose 5.7% from the year-ago quarter.
How is Maximus Faring?
The company maintains strong relationships with governments, and the long-term contracts provided by the government create a predictable recurring revenue stream. MMS seeks long-term relationships with clients in both existing and adjacent markets.
Maximus also concentrates on expanding its foothold in clinical services, as well as long-term services and support. Longevity and complex health issues have increased the need for government social benefits and safety-net programs. We believe that this should continue driving demand for the company’s services.
Acquisitions enable MMS to expand its business processes, knowledge and client relationships, enhance technical capabilities, and gain additional skill sets. Strategic acquisitions also complement the company’s long-term organic growth strategy. In 2024, the company acquired part of a vendor who had performed IT services for Maximus over several years for $18 million in cash. The 2022 acquisition of Stirling Institute of Australia has strengthened its employment services. BZ Bodies' buyout has strengthened MMS’s services in the U.K.
Maximus banks on the subject matter expertise of its workforce in the critical aspects of the design, implementation, and operation of government health and human services programs. Its ability to deliver defined, measurable outcomes differentiates MMS.
The company generates a strong cash flow from operations due to its profitable business and efficient receivables management. In case of an urgent requirement for working capital, MMS can borrow $600 million via a credit agreement with JPMorgan Chase N.A. All these factors provide the company with a competitive edge over its peers.
In fiscal 2021, 2022, 2023 and 2024, Maximus paid out cash dividends of $68.8 million, $68.7 million, $68 million and $72.9 million, respectively. These steady payouts indicate the company’s commitment to creating value for shareholders and underline its confidence in its business.
MMS’s current ratio (a measure of liquidity) at the end of first-quarter fiscal 2025 was pegged at 1.72, higher than the industry’s 1.54. A current ratio of more than 1 indicates that the company should not have problems meeting its short-term obligations.
Zacks Rank & Other Stocks to Consider
MMS currently flaunts a Zacks Rank #1 (Strong Buy) at present.
Some other top-ranked stocks in the broader Zacks Business Services sector are AppLovin (APP - Free Report) and Climb Global Solutions, Inc. (CLMB - Free Report) .
AppLovin sports a Zacks Rank of 1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
APP has a long-term earnings growth expectation of 20%. It delivered a trailing four-quarter earnings surprise of 23.5%, on average.
Climb Global Solutions flaunts a Zacks Rank of 1 at present.
CLMB has a long-term earnings growth expectation of 12%. It delivered a trailing four-quarter earnings surprise of 59.3%, on average.